19th Annual BIO CEO & Investor Conference
As biotech IPO activity has cooled from its 2015 peak, companies are more deliberately weighing reverse mergers and other alternatives to benefiting from the capital in public markets. With post-election market uncertainty, does the IPO market for 2017 seek to rise, fall, or stay level? What markers should CEOs watch for to gauge their timing and choices? This session will feature experienced voices for explaining the practical techniques for getting into public markets and what investors are expecting to see in order to win their support.
Moderator: Stephen Thau, Partner, Morrison & Foerster